Clinical trials: Lipemia
Hypercholesterolemia
Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)
Primary Objective: To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab as add-on therapy to stable daily statin therapy with or without other lipid modifying therapy in comparison with…
- Trial name
- NCT02107898
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT)
- Where
- 32 sites in Japan
- Volunteers
- 216 people
- Sponsor
- Sanofi
Atherosclerotic Cardiovascular Disease, Hypercholesterolemia
A Real-world Study of Inclisiran Adherence, Treatment Patterns, Patient Characteristics, and Effectiveness in ASCVD Patients With Hypercholesterolemia, ASCVD-risk Equivalent Patients With Hypercholesterolemia and Familial Hypercholesterolemia
This was a descriptive, non-interventional, retrospective cohort study among patients with atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia, ASCVD-risk equivalent (ASCVD-RE) or familial hypercholesterolemia…
- Trial name
- NCT06507852
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- Novartis
Healthy, Hypercholesterolemia
Health Effects of Consuming Olive Pomace Oil
Healthy and at risk (hypercholesterolemic) subjects consumed during 4 weeks 45 g/d of either olive pomace oil (OPO) or sunflower oil (SO) as the only dietary fat in a randomized, crossover trial.
- Trial name
- ORUJOSALUD-2 (NCT04998695)
- Testing
- Olive pomace oil, Sunflower oil
- Where
- Spain
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Instituto de Ciencia y Tecnología de Alimentos y Nutrición
Hypercholesterolemia
A Study of MK-6213 Co-Administered With Atorvastatin in Participants With Hypercholesterolemia (MK-6213-006)
The purpose of this study is to test the safety and effectiveness of MK-6213 as compared to MK-6213/Atorvastatin in participants 18 to 75 years) with high cholesterol.
- Trial name
- NCT00687271
- Testing
- MK-6213, Atorvastatin calcium
- Volunteers
- 334 people
- Sponsor
- Merck Sharp & Dohme LLC
High Cholesterol
Effect of Herring Oil Concentrate on LDL Cholesterol Concentration in Adults
High cholesterol concentration is a major risk factor for cardiovascular disease (CVD), and consumption of fish has been associated with a lower CVD risk in several studies.
- Trial name
- NCT06364163
- Testing
- Herring oil concentrate, Control
- Where
- Norway
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Bergen
Hypercholesterolemia, Familial
Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To evaluate the efficacy and safety of the lipid drug Torcetrapib/atorvastatin in patients with genetically known disorder of extremely high…
- Trial name
- NCT00134511
- Testing
- Torcetrapib/atorvastatin
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 30 people
- Sponsor
- Pfizer
Heterozygous Familial Hypercholesterolemia, Premature Coronary Heart Disease
A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease…
- Trial name
- NCT06164730
- Testing
- VERVE-102
- Where
- 27 sites in United States, Australia and 4 more
- Volunteers
- 85 people
- Sponsor
- Verve Therapeutics, Inc.
Hyperchylomicronemia
CS-121 APOC3 Base Editing in Children and Adolescents With Hyperchylomicronemia
This is a Prospective, Single-center, Open-label, Single-arm Clinical Study to Evaluate the Safety and Efficacy of CS-121, an In Vivo Base Editing Therapy Delivered by Lipid Nanoparticles Targeting APOC3, in Children and…
- Trial name
- NCT07371767
- Testing
- CS-121
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Hyperlipidemias
Glucagon-like Peptide-2 Mediated Secretion of Stored Enteral Lipids
Some of the fat (triglyceride) from the food humans eat gets stored in the bowel. This triglyceride can then be released into the blood when another meal is consumed or in response to hormones.
- Trial name
- GLP-2 Biopsy (NCT03442972)
- Testing
- Teduglutide
- Where
- 2 sites in Canada
- Volunteers
- 21 people
- Sponsor
- University Health Network, Toronto
Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma
Cardiovascular diseases and cancers, the two leading causes of death in Canada, require cholesterol to sustain their progression.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreas Cancer, Metastatic Cancer
- Trial name
- NCT04862260
- Testing
- Cholesterol metabolism disruption
- Where
- 2 sites in Canada
- Volunteers
- 3 people
- Sponsor
- CHU de Quebec-Universite Laval
Hypercholesterolemia
A 6-Month Consumer Behavior Study of a Self-Management System (0803-084)(COMPLETED)
The purpose of this study is to evaluate the ability of patients with intermediate risk of heart disease to appropriately use a Self-Management System.
- Trial name
- NCT00092846
- Testing
- MK0803, lovastatin, Self-Management System
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hyperlipidemias
Effect of Probucol and/or Cilostazol on Mean IMT in Patients With Coronary Heart dIsease
The purpose of this study is to evaluate the additional effect of probucol or concomitant administration of cilostazol and probucol on mean carotid artery intima-media thickness (mean IMT) at year 1, 2, and 3.
- Trial name
- IMPACTonIMT (NCT01291641)
- Testing
- HMG-CoA Reductase Inhibitor, Probucol, Cilostazol
- Where
- 5 sites in South Korea
- Volunteers
- 342 people
- Sponsor
- Seoul National University Hospital
Hypercholesterolemia
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
The purpose of this placebo-controlled, double-blind study is to assess the effect of several doses of CAT-2054 on LDL-C in hypercholesterolemic patients on a stable dose of high-intensity statin, and to evaluate the safety and…
- Trial name
- NCT02608697
- Testing
- CAT-2054, Atorvastatin
- Where
- 34 sites in United States
- Volunteers
- 153 people
- Sponsor
- Catabasis Pharmaceuticals
Hypercholesterolemia
A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED)
This is a multicenter study to evaluate the safety and efficacy of ezetimibe/simvastatin versus rosuvastatin in participants with high cholesterol.
- Trial name
- NCT00479713
- Testing
- ezetimibe (+) simvastatin, Comparator : rosuvastatin calcium
- Volunteers
- 618 people
- Sponsor
- Organon and Co
Hypercholesterolemia, Coronary Heart Disease
Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)
In this study the effect of the switch to rosuvastatin from another statin (fluvastatin, pravastatin, simvastatin, atorvastatin) was evaluated in high-risk patients with and without evident CHD and LDL-C ≥ 3.2 mmol/l.
- Trial name
- NCT00396110
- Volunteers
- 3,889 people
- Sponsor
- AstraZeneca
Hypercholesterolemia
Blood Lipid-lowering Effect of Brown Alga Ecklonia Cava
The investigators performed a 12-week, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Ecklonia cava extract on hyperlipidemia.
- Trial name
- NCT02091024
- Testing
- ECE (Ecklonia cava extract)
- Where
- South Korea
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Chonbuk National University Hospital
Dysbetalipoproteinemia
DARK STUDY "DysbetalipoproteinemiA and atheRoma Risk"
Dysbetalipoproteinemia (type III, Fredrickson's classification) is a rare metabolic disorder. It results from a defect in the clearance of VLDL and chylomicron remnants due to homozygous APOE2 variants or heterozygous APOE…
- Trial name
- DARK (NCT01760265)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Hospices Civils de Lyon
Diabete Mellitus, Prediabetes
Amelioration of Lipid Profile Through Date Cider-vinegar Along With 5:2 Intermittent Fasting
A common metabolic abnormality in hyperglycemic individuals, dyslipidemia is strongly linked to an increased risk of cardiovascular illness.
- Conditions
- Diabete Mellitus, Prediabetes, Hyperlipidemia
- Trial name
- NCT07710898
- Testing
- Control Group (T 0 ), Experimental Group (T 1 ), Experimental Group (T 2 )
- Where
- Pakistan
- Volunteers
- 108 people
- Sponsor
- University of Lahore
Hypercholesterolaemia
An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
Primary Objective: To evaluate the effect of alirocumab on low-density lipoprotein cholesterol (LDL-C) levels after 8 weeks of treatment in heterozygous familial hypercholesterolemia (heFH) participants aged of 8 to 17 years…
- Trial name
- ODYSSEY KIDS (NCT02890992)
- Testing
- alirocumab SAR236553 (REGN727), statins, ezetimibe
- Where
- 16 sites in United States, Canada and 8 more
- Volunteers
- 42 people
- Sponsor
- Sanofi
Hyperlipidemia, Periodontal Disease
Is There a Relationship Between Hyperlipidemia and Periodontitis?
The aim of present study is to investigate any relationship between hyperlipidemia and periodontal disease regarding the periodontal parameters and plasma lipid parameters, along with age, gender, brushing habit, body mass index…
- Trial name
- NCT02826720
- Testing
- No intervention was applied
- Volunteers
- 160 people
- Sponsor
- Marmara University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.